Sienna Biopharmaceuticals (SNNA) Stock Price, News & Analysis

Company Overview

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Key Stats

• Today's Range: $0.11 to $0.17
• 50-Day Range: $0.14 to $0.14
• 52-Week Range: $0.06 to $3.80
• Volume: 13.32 million shs
• Average Volume: 1.87 million shs
• Market Capitalization: $4.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SNNA Stock Analysis - Frequently Asked Questions

How were Sienna Biopharmaceuticals' earnings last quarter?

Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) posted its quarterly earnings results on Thursday, March, 14th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.83) by $0.10.

When did Sienna Biopharmaceuticals IPO?

Sienna Biopharmaceuticals (SNNA) raised $64 million in an IPO on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets served as the underwriters for the IPO.

What other stocks do shareholders of Sienna Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sienna Biopharmaceuticals investors own include SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Protalix BioTherapeutics (PLX), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Motif Bio (MTFB) and Ritter Pharmaceuticals (RTTR).

Company Calendar

• Last Earnings: 3/14/2019
• Today: 7/26/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SNNA
• CIK: 1656328
• Web: www.siennabio.com
• Phone: (818) 629-2256
• Fax: N/A
• Employees: 39
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$73.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -177.36%
• Return on Assets: -52.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.27
• Quick Ratio: 15.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.27 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 30,908,000
• Free Float: N/A
• Market Cap: $4.20 million
• Optionable: Not Optionable
• Beta: 2.67